Semax is a synthetic peptide based on the ACTH (4-10) fragment, modified for stability and stripped of hormonal activity. It has become one of the most studied nootropic peptides, with particular interest in its robust neurotrophic factor expression effects.
Research Applications
Neuroprotection (stroke, TBI models), cognitive enhancement, BDNF expression research, attention and memory studies, and optic nerve damage models.
Dosage Information (Research Use)
Research protocols: 200-600 mcg/day, intranasal or subcutaneous. Courses of 10-30 days in published studies. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Short plasma half-life, but CNS effects are sustained for hours due to neurotrophic cascades.
Reported Observations in Literature
Minimal adverse effects in published research. No adrenal stimulation despite ACTH origin. Occasional mild headache reported.
Key Research References
- Dolotov OV, et al. “Semax, an ACTH(4-10) analog with nootropic properties, activates BDNF and trkB in the hippocampus.” Brain Res. 2006
- Ashmarin IP, et al. “The Mechanisms of Interaction Between Semax and Enkephalin-Degrading Enzymes.” Neurosci Behav Physiol. 2001